Track topics on Twitter Track topics that are important to you
12th Septmber 2013: Imperial Innovations Group plc (AIM: IVO, “Innovations”), the leading technology commercialisation and investment group, announces that portfolio company Circassia, the specialty biopharmaceutical company focused on allergy, has achieved successful results from a phase II clinical study of its house dust mite allergy treatment.
Patients who received four doses of the treatment over 12 weeks had significantly improved allergy symptoms one year after the start of the trial compared with placebo, meeting the study’s long-term primary endpoint.
The trial was conducted in Toronto, Canada, where 172 volunteers with confirmed house dust mite allergy received one of four treatment regimens or placebo. Investigators measured patients’ allergy symptoms when exposed to house dust mite allergens, at the start and during the 12-month study. Circassia has submitted the study results for presentation at a leading scientific conference.
House dust mites are found widely throughout homes, in bedding, carpets, soft furnishings and clothing. Allergy to proteins in the mites’ droppings is extremely common, and often associated with asthma. In the United States and Europe, approximately one in four people are sensitised to house dust mites, with more people having allergic responses than to any other common allergen. House dust mite allergy is a perennial condition that can impact sufferers’ education, work, quality of life and social activities.
Other allergies for which Circassia is developing a treatment include cat, currently in phase III trials and grass, currently in phase II.
Russ Cummings, CEO of Innovations, said: “The long term success of Circassia’s house dust mite allergy treatment endorses the potential of its allergy treatment platform. This progress is a great demonstration of the value that is being developed within Innovations’ portfolio of technologies."
Imperial Innovations Group Plc +44 (0)20 7594 6506
Russ Cummings, Chief Executive Officer
Terry Nicklin, Director of Communications
College Hill +44 (0)20 7457 2020
Adrian Duffield/Tim Watson/Rozi Morris
J.P. Morgan Cazenove +44 (0)20 7742 4000
Michael Wentworth Stanley/Alec Pratt
Notes to editors
About Circassia – www.circassia.co.uk
Circassia was founded by a team of highly experienced biotechnology scientists and entrepreneurs. The company is based in the UK on the Oxford Science Park, and its joint venture with McMaster University (Adiga Life Sciences Inc) is located in Hamilton, Canada. Circassia’s ToleroMune® technology was developed originally by scientists at Imperial College, London. Having successfully completed five fundraising rounds, Circassia has raised approximately £105 million ($178 million) and is backed by a syndicate of world-class institutional investors, including Imperial Innovations and Invesco Perpetual.
Innovations raised £140 million in January 2011. In the year to 31 July 2012, it invested £37.9 million (2011: £35.1 million) in 29 ventures, and made 11 investments in new companies. In July 2013, Innovations obtained a £30m, 12-year loan from the European Investment Bank (EIB) to invest in the biotech and therapeutics sectors.
In its current portfolio of around 80 companies, Innovations’ assets include Veryan, a medical devices business developing improved stent technologies and Acunu, a Cambridge-associated business specialising in ‘big data’, with technology that enables its customers to create large, quickly accessible databases using low cost hardware.
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...